Ontology highlight
ABSTRACT:
SUBMITTER: Hackel MA
PROVIDER: S-EPMC8846401 | biostudies-literature | 2022 Feb
REPOSITORIES: biostudies-literature
Hackel Meredith A MA Karlowsky James A JA Canino Michele A MA Sahm Daniel F DF Scangarella-Oman Nicole E NE
Antimicrobial agents and chemotherapy 20211220 2
Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (<i>n </i>= 333) and Gram-positive (<i>n </i>= 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. Given gepotidacin's <i>in vitro</i> activity against the anaerobic isolates tested, further study is warranted to better understand the utility of gepotidacin in the tre ...[more]